The truth about Tamiflu? Zanamivir should be inhaled, not nebulised
- PMID: 20071426
- PMCID: PMC3234150
- DOI: 10.1136/bmj.c131
The truth about Tamiflu? Zanamivir should be inhaled, not nebulised
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.BMJ. 2009 Dec 8;339:b5106. doi: 10.1136/bmj.b5106. BMJ. 2009. PMID: 19995812 Free PMC article.
Similar articles
-
Fatal respiratory events caused by zanamivir nebulization.Clin Infect Dis. 2010 Jul 1;51(1):121. doi: 10.1086/653450. Clin Infect Dis. 2010. PMID: 20518681 No abstract available.
-
Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza.N Engl J Med. 2010 Jan 7;362(1):88-9. doi: 10.1056/NEJMc0910893. Epub 2009 Dec 23. N Engl J Med. 2010. PMID: 20032317 No abstract available.
-
Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.Scand J Infect Dis. 2011 Jul;43(6-7):495-503. doi: 10.3109/00365548.2011.556144. Epub 2011 Feb 10. Scand J Infect Dis. 2011. PMID: 21309638
-
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Expert Rev Anti Infect Ther. 2011. PMID: 21973296 Review.
-
Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.Infect Disord Drug Targets. 2013 Feb;13(1):34-45. doi: 10.2174/18715265112129990006. Infect Disord Drug Targets. 2013. PMID: 23675925 Review.
Cited by
-
Antiviral treatment for viral pneumonia: current drugs and natural compounds.Virol J. 2025 Mar 6;22(1):62. doi: 10.1186/s12985-025-02666-1. Virol J. 2025. PMID: 40050867 Free PMC article. Review.
References
-
- Relenza. Highlights of prescribing information (package insert). Available at: http://us.gsk.com/products/assets/us_relenza.pdf (Accessed 9 December 2009.)
-
- Summary of the product characteristics. www.lakemedelsverket.se/SPC_PIL/Pdf/enhumspc/Relenza%20inhalation%20powd... (Accessed 9 December 2009.)
-
- US Food and Drug Administration. Relenza (zanamivir) inhalation powder. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedica... (Accessed 9 December 2009.)
-
- FDA Safety. Important drug warning. Subject: Relenza (zanamivir) inhalation powder must not be nebulised. www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforH... (Accessed 9 December 2009.)
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources